From the Research
To stop caplacizumab (Cablivi), you should always consult with your healthcare provider first rather than discontinuing it independently. Caplacizumab is typically administered for acquired thrombotic thrombocytopenic purpura (aTTP) and stopping it prematurely could lead to serious complications including recurrence of aTTP. The standard treatment course involves daily injections during plasma exchange and for 30 days after stopping plasma exchange. Your doctor may extend treatment for up to 28 additional days if needed. When discontinuation is appropriate, your healthcare provider will monitor your ADAMTS13 activity levels to ensure they have normalized, as low levels indicate risk of relapse. Side effects like bleeding may prompt consideration of stopping treatment, but this decision should be made by your healthcare team. After stopping caplacizumab, you'll need continued monitoring for any signs of aTTP recurrence such as fatigue, fever, or unusual bruising. None of the provided studies 1, 2, 3, 4, 5 directly address the discontinuation of caplacizumab, but the general principle of consulting a healthcare provider before stopping any medication, especially one used for a serious condition like aTTP, is a crucial aspect of patient care. Given the potential for severe complications, the decision to stop caplacizumab should be based on the most recent and highest quality clinical guidelines and patient-specific factors, rather than the studies provided which do not directly pertain to the use or discontinuation of caplacizumab.